1. Physical exercise halts further functional decline in an animal model for Charcot–Marie–Tooth disease 1X at an advanced disease stage.
- Author
-
Klein, Dennis, Yépez, Maria Grijalva, and Martini, Rudolf
- Subjects
- *
NEURITIS , *PERIPHERAL neuropathy , *EXERCISE physiology , *LONG-distance running , *TREATMENT effectiveness - Abstract
Background and Aims Methods Results Interpretation Charcot–Marie–Tooth (CMT) type 1 neuropathies are the most common inherited diseases of the peripheral nervous system. Although more than 100 causative genes have been identified so far, therapeutic options are still missing. We could previously identify that early‐onset physical exercise (voluntary wheel running, VWR) dampens peripheral nerve inflammation, improves neuropathological alterations, and clinical outcome in Cx32def mice, a model for CMT1X. We here investigate the clinical and histopathological effect of late‐onset exercise in Cx32def mice at an advanced disease stage.Nine‐month‐old Cx32def mice were allowed to run for 4 days/week on a commercially available running wheel for 3 months, with timely limited access to running wheels, representing a running distance of ~2000 m. Control mutants had no access to running wheels. Afterward, mice were investigated by distinct functional tests and by immunohistochemical and electron microscopical techniques.We found that late‐onset physical exercise (late VWRlim) prevented the robust functional decline in 12‐month‐old Cx32def mice. This was accompanied by improved neuromuscular innervation of distal muscles and axonal preservation in femoral quadriceps nerves. In contrast to a “pre‐symptomatic” start of physical exercise in Cx32def mice, late‐onset VWR did not alter nerve inflammation and myelin thickness at 12 months of age.We conclude that VWR has robust beneficial effects on nerve function in Cx32def mice, even when applied at a progressed disease stage. These results have important translational implications, suggesting that physical exercise might be an effective treatment option for CMT1 patients, even when disease symptoms have already progressed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF